Maura, Géric <br/><br/>
Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.  [electronic resource] 

 -  Pharmacotherapy  01 2018 
 - 6-18 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1875-9114 
<br/><br/><label>Standard No.: </label>10.1002/phar.2046  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Age Factors<br/>Aged<br/>Aged, 80 and over<br/>Anticoagulants--administration & dosage<br/>Atrial Fibrillation--complications<br/>Cohort Studies<br/>Dabigatran--administration & dosage<br/>Databases, Factual<br/>Dose-Response Relationship, Drug<br/>Female<br/>France<br/>Hemorrhage--chemically induced<br/>Hospitalization--statistics & numerical data<br/>Humans<br/>International Normalized Ratio<br/>Male<br/>Middle Aged<br/>Rivaroxaban--administration & dosage<br/>Stroke--prevention & control<br/>Vitamin K--antagonists & inhibitors<br/>Assessment of Medication Adherence